Patient characteristics at baseline in patients who were HIV+ and HIV– with HHV8+ MCD
| Patients . | All N = 99, (%) . | HIV+ n = 73, (%) . | HIV– n = 26, (%) . |
|---|---|---|---|
| Age (median, y) | 45 | 42 | 65 |
| Male | 76 (77) | 55 (75) | 21 (81) |
| Ethnicity | |||
| Western Africa | 46 | 35 | 11 |
| Northern Africa | 9 | 6 | 3 |
| Caucasian | 43 | 32 | 11 |
| Other | 1 | 0 | 1 |
| Symptoms | |||
| Fever | 89 (90) | 67 (92) | 22 (85) |
| Lymphadenopathy | 97 (98) | 71 (97) | 26 (100) |
| Splenomegaly | 82 (83) | 63 (86) | 19 (73) |
| Edema | 37 (37) | 24 (33) | 13 (50) |
| Lung involvement | 36 (37) | 24 (33) | 12 (46) |
| Skin involvement | 5 (5) | 4 (5) | 1 (4) |
| Nasal obstruction | 18 (18) | 15 (21) | 3 (12) |
| AIHA | 23 (23) | 17 (23) | 6 (23) |
| Kaposi sarcoma | 33 (33) | 29 (40) | 4 (15) |
| Hemophagocytosis | 37 (38) | 30 (41) | 7 (29) |
| Hemoglobin (g/dL, median) | 8.7 | 8.6 | 9.4 |
| Platelets (× 109/L, median) | 147 | 116 | 173 |
| Lymphocytes (× 106/L, median) | 1540 | 1490 | 1780 |
| CRP (mg/L, median) | 120 | 128 | 117 |
| Albumin (g/L, median) | 28 | 28 | 28 |
| Gamma globulins (g/L, median) | 26.3 | 26.2 | 25 |
| CD4+ T cells (× 106/L, median) | 315 | 233 | 740 |
| CD19+ B cells (× 106/L, median) | 247 | 208 | 278 |
| Plasma HIV RNA (log copies per mL, median) | na | 2.3 | na |
| ≤50 copies per mL | na | 18 (25) | na |
| Blood HHV8 DNA (log copies per mL, median) | 5.11 | 5.14 | 5.04 |
| Patients . | All N = 99, (%) . | HIV+ n = 73, (%) . | HIV– n = 26, (%) . |
|---|---|---|---|
| Age (median, y) | 45 | 42 | 65 |
| Male | 76 (77) | 55 (75) | 21 (81) |
| Ethnicity | |||
| Western Africa | 46 | 35 | 11 |
| Northern Africa | 9 | 6 | 3 |
| Caucasian | 43 | 32 | 11 |
| Other | 1 | 0 | 1 |
| Symptoms | |||
| Fever | 89 (90) | 67 (92) | 22 (85) |
| Lymphadenopathy | 97 (98) | 71 (97) | 26 (100) |
| Splenomegaly | 82 (83) | 63 (86) | 19 (73) |
| Edema | 37 (37) | 24 (33) | 13 (50) |
| Lung involvement | 36 (37) | 24 (33) | 12 (46) |
| Skin involvement | 5 (5) | 4 (5) | 1 (4) |
| Nasal obstruction | 18 (18) | 15 (21) | 3 (12) |
| AIHA | 23 (23) | 17 (23) | 6 (23) |
| Kaposi sarcoma | 33 (33) | 29 (40) | 4 (15) |
| Hemophagocytosis | 37 (38) | 30 (41) | 7 (29) |
| Hemoglobin (g/dL, median) | 8.7 | 8.6 | 9.4 |
| Platelets (× 109/L, median) | 147 | 116 | 173 |
| Lymphocytes (× 106/L, median) | 1540 | 1490 | 1780 |
| CRP (mg/L, median) | 120 | 128 | 117 |
| Albumin (g/L, median) | 28 | 28 | 28 |
| Gamma globulins (g/L, median) | 26.3 | 26.2 | 25 |
| CD4+ T cells (× 106/L, median) | 315 | 233 | 740 |
| CD19+ B cells (× 106/L, median) | 247 | 208 | 278 |
| Plasma HIV RNA (log copies per mL, median) | na | 2.3 | na |
| ≤50 copies per mL | na | 18 (25) | na |
| Blood HHV8 DNA (log copies per mL, median) | 5.11 | 5.14 | 5.04 |
AIHA, autoimmune hemolytic anemia; na, not applicable.